論文 - 大家　基嗣

Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.

Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, Kakehi Y, Nonomura N, Ogawa O, Oya M, Suzuki K, Saito A, Asakawa K, Uno S, Naito S

International journal of clinical oncology 2022年08月

ISSN  1341-9625

• Access to Document (DOI)

Iliopsoas abscess in patients receiving hemodialysis: a case series and a literature survey

Oshida Takuma, Yoshida Tadashi, Itoh Hiroshi, Oya Mototsugu

RENAL REPLACEMENT THERAPY 8 （ 1 ）  2022年07月

• Access to Document (DOI)

Functional analysis of GCNT3 for cell migration and EMT of castration-resistant prostate cancer cells.

Yamamoto D, Sasaki K, Kosaka T, Oya M, Sato T

Glycobiology 2022年07月

ISSN  0959-6658

　概要を見る

Castration-resistant prostate cancer (CRPC) is a malignant tumor that is resistant to androgen deprivation therapy. Treatments for CRPC are limited, and no diagnostic markers are currently available. O-glycans are known to play an important role in cell proliferation, migration, invasion, and metastasis of cancer cells. However, the differences in the O-glycan expression profiles for normal prostate cancer (PCa) cells compared to CRPC cells have not yet been investigated. In this study, the saccharide primer method was employed to analyze the O-glycans expressed in CRPC cells. Expression levels of core 4-type O-glycans were significantly increased in CRPC cells. Furthermore, the expression level of N-Acetylglucosaminyltransferase 3 (GCNT3), a core 4-type O-glycan synthase gene, was increased in CRPC cells. The expression of core 4-type O-glycans and GCNT3 was presumed to be regulated by androgen deprivation. GCNT3 knockdown induced cell migration and epithelial-mesenchymal transition (EMT). These observations elucidate the mechanism of acquisition of castration resistance in PCa and offer new possibilities for the development of diagnostic markers and therapeutic targets in the treatment of PCa.

• Access to Document (DOI)

Characterization of aldosterone-producing cell cluster (APCC) at single-cell resolution.

Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, Suematsu M, Umezawa Y, Oya M, Kosaka T, Seki M, Suzuki Y, Horiuchi Y, Ogawa Y, Nishimoto K

The Journal of clinical endocrinology and metabolism 2022年07月

ISSN  0021-972X

　概要を見る

CONTEXT: The adrenal cortex consists of zona glomerulosa (ZG), fasciculata (ZF), and reticularis. Aldosterone-producing cell clusters that strongly express aldosterone synthase (CYP11B2) are frequently found in adult adrenals and harbor somatic mutations that are also detected in aldosterone-producing adenomas (APAs). Primary aldosteronism is mainly caused by APAs or idiopathic hyperaldosteronism (IHA). We presume that APCCs are causing IHA and are precursors of APAs. However, the gene expression characteristics and especially the development of APCC are not well understood. OBJECTIVE: This study aimed to analyze the transcriptome of APCC at single-cell resolution and infer the developmental trajectory. METHODS: Single-cell RNA sequencing (scRNA-seq) of two adult adrenals was performed. RESULTS: Immunohistochemical analyses confirmed the two adrenals had APCCs. scRNA-seq data of 2,928 adrenal cells were obtained and 1,765 adrenocortical cells were identified based on unsupervised clustering and the marker gene expression. The adrenocortical cells were divided into 6 clusters, of which three clusters (923 cells) were composed of APCC/ZG cells. By further sub-clustering, the APCC/ZG cells were divided into three clusters (clusters C1, C2, and C3), we finally identified APCC-cluster (C3) and ZG-cluster (C1). Cluster C2 seemed to be ZG-to-ZF transitional cells. RNA velocity analysis inferred the developmental direction from cluster ZG-cluster-C1 to APCC-cluster-C3. The scRNA-seq additionally revealed that many CYP11B2-positive cells were positive for CYP11B1 and/or CYP17A1, which were essential for cortisol but not for aldosterone production. CONCLUSIONS: Our results revealed the gene expression characteristics of APCC at single-cell resolution and show that some ZG cells remodel to APCC.

• Access to Document (DOI)

Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy.

Komori T, Kosaka T, Watanabe K, Tanaka T, Yasumizu Y, Hongo H, Mikami S, Ohashi T, Oya M

IJU case reports （IJU Case Reports）  5 （ 4 ） 233 - 236 2022年07月

ISSN  2577-171X

　概要を見る

Introduction: Treatment strategy for castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. Case presentation: We described a case of castration-resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate-specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate-specific antigen progression-free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. Conclusion: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration-resistant prostate cancer with neuroendocrine differentiation.

• Access to Document (DOI)

Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma.

Kufukihara R, Tanaka N, Takamatsu K, Niwa N, Fukumoto K, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Aimono E, Nishihara H, Mizuno R, Oya M

British journal of cancer （British Journal of Cancer）  2022年06月

ISSN  0007-0920

　概要を見る

Background: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. Methods: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. Results: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. Conclusion: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.

• Access to Document (DOI)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.

Kamisawa K, Kosaka T, Nakamura K, Yasumizu Y, Hongo H, Takeda T, Matsumoto K, Nishihara H, Oya M

Cancer science 2022年06月

ISSN  1347-9032

　概要を見る

The purpose of this study was to investigate factors predicting the sensitivity to cabazitaxel therapy in metastatic castration-resistant prostate cancer (mCRPC) patients with phosphatase and tensin homolog deleted from chromosome 10 (PTEN) alterations. This single-institution, retrospective study included 12 mCRPC patients with PTEN alterations who had received cabazitaxel therapy. Five patients (41%) responded to cabazitaxel therapy with a prostate-specific antigen (PSA) level decline of ≥30% from baseline, and all of them had responded to prior docetaxel therapy with a PSA decline of ≥30%. None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. Of the seven patients who did not respond to cabazitaxel and whose PSA declined from baseline was <30%, five (71%) were also refractory to prior docetaxel therapy. The PSA responses to docetaxel and cabazitaxel were significantly correlated (p = 0.027). Kaplan-Meier analysis revealed that progression-free survival (PFS) for cabazitaxel was significantly shorter for prior docetaxel nonresponders (3.3 versus 9.1 months, p = 0.028). Multivariate analysis revealed that a poor response to prior docetaxel (PSA decline < 30%) (hazard ratio [HR] = 6.382, 95% confidence interval [CI] 1.172-34.750, p = 0.032) and baseline PSA of ≥20 ng/ml (HR = 33.584, 95% CI 2.332-483.671, p = 0.010) were independent prognostic factors for PFS with cabazitaxel therapy. These results demonstrate cross-resistance between docetaxel and cabazitaxel. The response to prior docetaxel therapy can influence the sensitivity to cabazitaxel therapy in mCRPC patients with PTEN alterations.

• Access to Document (DOI)

A low subcutaneous fat mass is a risk factor for the development of inguinal hernia after radical prostatectomy.

Umeda K, Takeda T, Hakozaki K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M

Langenbeck's archives of surgery 2022年06月

ISSN  1435-2443

• Access to Document (DOI)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.

Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M

BMC medical genomics 15 （ 1 ） 138 2022年06月

• Access to Document (DOI)

Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.

Oya M, Kaneko S, Imai T, Tsujino T, Sunaya T, Okayama Y

Cancer chemotherapy and pharmacology 89 （ 6 ） 761 - 772 2022年06月

ISSN  0344-5704

• Access to Document (DOI)

Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review.

Masuda T, Kosaka T, Nakamura K, Hongo H, Yuge K, Nishihara H, Oya M

BMC medical genomics 15 （ 1 ） 118 2022年05月

• Access to Document (DOI)

特集 腹部の最新画像情報2022 症例 術後早期に遠隔転移を認めた表在性膀胱小細胞癌の2例

竹下 諒, 有田 祐起, 秋田 大宇, 三上 修治, 田中 伸之, 奥田 茂男, 大家 基嗣, 陣崎 雅弘

臨床放射線 （金原出版）  67 （ 5 ） 505 - 510 2022年05月

ISSN  00099252

• Access to Document (DOI)
• CiNii Research

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.

Shigeta K, Matsumoto K, Tanaka N, Mikami S, Kosaka T, Yasumizu Y, Takeda T, Mizuno R, Kikuchi E, Oya M

International journal of molecular sciences 23 （ 9 ）  2022年05月

• Access to Document (DOI)

Deep Learning Algorithm for Fully Automated Detection of Small (≤4 cm) Renal Cell Carcinoma in Contrast-Enhanced Computed Tomography Using a Multicenter Database.

Toda N, Hashimoto M, Arita Y, Haque H, Akita H, Akashi T, Gobara H, Nishie A, Yakami M, Nakamoto A, Watadani T, Oya M, Jinzaki M

Investigative radiology 57 （ 5 ） 327 - 333 2022年05月

ISSN  0020-9996

• Access to Document (DOI)

Prospective study of tadalafil treatment in patients treated with prostate brachytherapy in Japan.

Hayakawa N., Mizuno R., Shiraishi Y., Tanaka T., Matsumoto K., Kosaka T., Ohashi T., Kikuchi E., Shigematsu N., Oya M.

RADIOTHERAPY AND ONCOLOGY 170   S1618 - S1618 2022年05月

ISSN  0167-8140

Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation.

Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y

Abdominal radiology (New York) 47 （ 6 ） 2178 - 2186 2022年04月

ISSN  2366-004X

• Access to Document (DOI)

Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.

Omura M, Kikuchi E, Shigeta K, Ogihara K, Hakozaki K, Hara S, Shirotake S, Ide H, Yoshimine S, Ohigashi T, Mizuno R, Oya M

Japanese journal of clinical oncology 52 （ 4 ） 388 - 396 2022年04月

ISSN  0368-2811

• Access to Document (DOI)

増刊号特集 専門性と多様性を両立させる! 泌尿器科外来ベストNAVI 企画にあたって 専門性と多様性を両立させる! 泌尿器科外来ベストNAVI

大家 基嗣

臨床泌尿器科 （株式会社医学書院）  76 （ 4 ） 7 - 7 2022年04月

ISSN  03852393

• Access to Document (DOI)
• CiNii Research

Outcomes of sorafenib treatment of advanced renal cell carcinoma according to IMDC risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib.

Inamoto T, Azuma H, Adachi M, Okayama Y, Sunaya T, Oya M

Future oncology (London, England) 18 （ 11 ） 1371 - 1380 2022年04月

ISSN  1479-6694

• Access to Document (DOI)

Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey.

Sanjo T, Tanaka N, Shinojima T, Yasumizu Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mizuno R, Asanuma H, Oya M

Asian journal of endoscopic surgery 2022年03月

ISSN  1758-5902

• Access to Document (DOI)